AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG)‘s stock had its “hold” rating restated by analysts at Janney Montgomery Scott in a note issued to investors on Tuesday, October 17th.
Other analysts have also recently issued reports about the stock. BidaskClub raised shares of AMAG Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, July 6th. Zacks Investment Research raised shares of AMAG Pharmaceuticals from a “hold” rating to a “buy” rating and set a $22.00 price objective for the company in a research note on Tuesday, July 11th. Deutsche Bank AG set a $24.00 target price on shares of AMAG Pharmaceuticals and gave the company a “hold” rating in a report on Friday, July 7th. Citigroup Inc. cut their price objective on shares of AMAG Pharmaceuticals to $24.00 and set a “hold” rating on the stock in a report on Friday, July 7th. Finally, Cantor Fitzgerald reissued a “hold” rating and issued a $23.00 target price on shares of AMAG Pharmaceuticals in a research report on Monday, June 26th. Three equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and three have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $25.83.
AMAG Pharmaceuticals (NASDAQ AMAG) opened at 15.35 on Tuesday. AMAG Pharmaceuticals has a 1-year low of $14.90 and a 1-year high of $36.83. The firm’s 50-day moving average price is $18.22 and its 200-day moving average price is $18.88. The firm’s market capitalization is $541.67 million.
AMAG Pharmaceuticals (NASDAQ:AMAG) last released its earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.40) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.58) by $0.18. AMAG Pharmaceuticals had a negative net margin of 7.58% and a negative return on equity of 4.81%. The firm had revenue of $158.39 million during the quarter, compared to analysts’ expectations of $158.83 million. During the same period in the previous year, the company earned $1.45 EPS. AMAG Pharmaceuticals’s revenue for the quarter was up 24.3% on a year-over-year basis. On average, equities research analysts predict that AMAG Pharmaceuticals will post ($1.39) EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This article was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The original version of this article can be viewed at https://www.dispatchtribunal.com/2017/10/28/amag-pharmaceuticals-inc-amag-rating-reiterated-by-janney-montgomery-scott.html.
A number of hedge funds have recently added to or reduced their stakes in AMAG. State of Alaska Department of Revenue lifted its stake in AMAG Pharmaceuticals by 81.3% during the second quarter. State of Alaska Department of Revenue now owns 6,871 shares of the specialty pharmaceutical company’s stock valued at $126,000 after purchasing an additional 3,081 shares during the last quarter. Municipal Employees Retirement System of Michigan lifted its stake in AMAG Pharmaceuticals by 6.6% during the second quarter. Municipal Employees Retirement System of Michigan now owns 8,280 shares of the specialty pharmaceutical company’s stock valued at $152,000 after purchasing an additional 510 shares during the last quarter. Mason Street Advisors LLC lifted its stake in AMAG Pharmaceuticals by 7.4% during the first quarter. Mason Street Advisors LLC now owns 8,030 shares of the specialty pharmaceutical company’s stock valued at $181,000 after purchasing an additional 554 shares during the last quarter. Sei Investments Co. lifted its stake in AMAG Pharmaceuticals by 0.7% during the first quarter. Sei Investments Co. now owns 8,342 shares of the specialty pharmaceutical company’s stock valued at $188,000 after purchasing an additional 54 shares during the last quarter. Finally, Aperio Group LLC acquired a new stake in AMAG Pharmaceuticals during the third quarter valued at approximately $198,000.
AMAG Pharmaceuticals Company Profile
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.